Nigrosome 1 Detection at 3T MRI for the Diagnosis of Early-Stage Idiopathic Parkinson Disease: Assessment of Diagnostic Accuracy and Agreement on Imaging Asymmetry and Clinical Laterality

REFERENCES

1. 1.↵
   2. Damier P,
   3. Hirsch EC,
   4. Agid Y, et al

   . The substantia nigra of the human brain, I: nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999;122(pt 8):1421–36 doi:10.1093/brain/122.8.1421 pmid:10430829

   Abstract/FREE Full Text
2. 2.↵
   2. Damier P,
   3. Hirsch EC,
   4. Agid Y, et al

   . The substantia nigra of the human brain, II: patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999;122(pt 8):1437–48 doi:10.1093/brain/122.8.1437 pmid:10430830

   Abstract/FREE Full Text
3. 3.↵
   2. Kwon DH,
   3. Kim JM,
   4. Oh SH, et al

   . Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012;71:267–77 doi:10.1002/ana.22592 pmid:22367998

   CrossRefPubMed
4. 4.↵
   2. Lotfipour AK,
   3. Wharton S,
   4. Schwarz ST, et al

   . High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging 2012;35:48–55 doi:10.1002/jmri.22752 pmid:21987471

   CrossRefPubMed
5. 5.↵
   2. Blazejewska AI,
   3. Schwarz ST,
   4. Pitiot A, et al

   . Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. Neurology 2013;81:534–40 doi:10.1212/WNL.0b013e31829e6fd2 pmid:23843466

   CrossRefPubMed
6. 6.↵
   2. Cosottini M,
   3. Frosini D,
   4. Pesaresi I, et al

   . MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease. Radiology 2014;271:831–38 doi:10.1148/radiol.14131448 pmid:24601752

   CrossRefPubMed
7. 7.↵
   2. Schwarz ST,
   3. Afzal M,
   4. Morgan PS, et al

   . The ‘swallow tail’ appearance of the healthy nigrosome: a new accurate test of Parkinson's disease—a case-control and retrospective cross-sectional MRI study at 3T. PLoS One 2014;9:e93814 doi:10.1371/journal.pone.0093814 pmid:24710392

   CrossRefPubMed
8. 8.↵
   2. Cosottini M,
   3. Frosini D,
   4. Pesaresi I, et al

   . Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease. AJNR Am J Neuroradiol 2015;36:461–66 doi:10.3174/ajnr.A4158 pmid:25376811

   Abstract/FREE Full Text
9. 9.↵
   2. Mueller C,
   3. Pinter B,
   4. Reiter E, et al

   . Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7T MRI. Neurology 2014;82:1752 doi:10.1212/WNL.0000000000000398 pmid:24821935

   FREE Full Text
10. 10.↵
    2. Fahn S

    . Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003;991:1–14 doi:10.1111/j.1749-6632.2003.tb07458.x pmid:12846969

    CrossRefPubMedWeb of Science
11. 11.↵
    2. van der Hoorn A,
    3. Bartels AL,
    4. Leenders KL, et al

    . Handedness and dominant side of symptoms in Parkinson's disease. Parkinsonism Relat Disord 2011;17:58–60 doi:10.1016/j.parkreldis.2010.10.002 pmid:20974546

    CrossRefPubMed
12. 12.↵
    2. Jin S,
    3. Oh M,
    4. Oh SJ, et al

    . Differential diagnosis of parkinsonism using dual-phase F-18 FP-CIT PET imaging. Nucl Med Mol Imaging 2013;47:44–51 doi:10.1007/s13139-012-0182-4 pmid:24895507

    CrossRefPubMed
13. 13.↵
    2. Hughes AJ,
    3. Daniel SE,
    4. Kilford L, et al

    . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–84 doi:10.1136/jnnp.55.3.181 pmid:1564476

    Abstract/FREE Full Text
14. 14.↵
    2. Hoehn MM,
    3. Yahr MD

    . Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–42 doi:10.1212/WNL.17.5.427 pmid:6067254

    FREE Full Text
15. 15.↵
    2. Scheltens P,
    3. Barkhof F,
    4. Leys D, et al

    . A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993;114:7–12 doi:10.1016/0022-510X(93)90041-V pmid:8433101

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Booij J,
    3. Kemp P

    . Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 2008;35:424–38 doi:10.1007/s00259-007-0621-0 pmid:17968545

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Wang J,
    3. Zuo CT,
    4. Jiang YP, et al

    . 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol 2007;254:185–90 doi:10.1007/s00415-006-0322-9 pmid:17334953

    CrossRefPubMed
18. 18.↵
    2. Park E,
    3. Hwang YM,
    4. Lee CN, et al

    . Differential diagnosis of patients with inconclusive Parkinsonian features using [(18)F]FP-CIT PET/CT. Nucl Med Mol Imaging 2014;48:106–13 doi:10.1007/s13139-013-0253-1 pmid:24900150

    CrossRefPubMed
19. 19.↵
    2. Kempster PA,
    3. Gibb WR,
    4. Stern GM, et al

    . Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry 1989;52:72–76 doi:10.1136/jnnp.52.1.72 pmid:2709038

    Abstract/FREE Full Text
20. 20.↵
    2. Lee CS,
    3. Samii A,
    4. Sossi V, et al

    . In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493–503 doi:10.1002/1531-8249(200004)47:4<493::aid-ana13>3.0.co%3B2-4 pmid:10762161

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Schwarz ST,
    3. Bajaj N,
    4. Gowland PA, et al

    . MR imaging of the substantia nigra for the diagnosis of Parkinson disease. Radiology 2014;273:627–28 doi:10.1148/radiol.14141040 pmid:25340275

    CrossRefPubMed
22. 22.↵
    2. Cosottini M,
    3. Frosini D,
    4. Pesaresi I, et al

    . Response. Radiology 2014;273:628–29 pmid:25513662

    PubMed